Afya (NASDAQ:AFYA - Get Free Report) was downgraded by stock analysts at Wall Street Zen from a "buy" rating to a "hold" rating in a report released on Monday, Wall Street Zen reports.
Several other brokerages have also issued reports on AFYA. Weiss Ratings lowered shares of Afya from a "hold (c-)" rating to a "sell (d+)" rating in a report on Thursday, October 29th. Bradesco Corretora upgraded shares of Afya to an "outperform" rating and set a $17.00 target price on the stock in a research report on Thursday, September 24th. Bank of America upgraded shares of Afya from a "neutral" rating to a "buy" rating and set a $16.00 target price on the stock in a research report on Thursday, October 29th. JPMorgan Chase & Co. decreased their target price on shares of Afya from $19.00 to $17.50 and set an "overweight" rating on the stock in a research note on Tuesday, November 3rd. Finally, Citigroup upgraded shares of Afya from a "neutral" rating to a "buy" rating and lowered their price target for the stock from $16.00 to $12.00 in a report on Tuesday, November 3rd. Four research analysts have rated the stock with a Buy rating, three have issued a Hold rating and two have given a Sell rating to the stock. According to MarketBeat, the company currently has a consensus rating of "Hold" and a consensus target price of $15.18.
Get Our Latest Report on AFYA
Afya Stock Performance
Shares of Afya stock opened at $10.32 on Monday. The stock has a market cap of $967.19 million, a P/E ratio of 6.07, a P/E/G ratio of 1.66 and a beta of 0.43. The company has a quick ratio of 2.08, a current ratio of 2.08 and a debt-to-equity ratio of 0.38. Afya has a 12-month low of $9.66 and a 12-month high of $16.16. The business's 50 day moving average is $12.82 and its 200-day moving average is $14.00.
Afya (NASDAQ:AFYA - Get Free Report) last posted its quarterly earnings results on Friday, August 14th. The company reported $0.43 EPS for the quarter, topping analysts' consensus estimates of $0.40 by $0.03. Afya had a return on equity of 17.09% and a net margin of 20.48%. The business had revenue of $187.80 million during the quarter, compared to analysts' expectations of $189.62 million. Equities research analysts predict that Afya will post 1.68 earnings per share for the current fiscal year.
Insiders Place Their Bets
In other Afya news, insider Santos Welder Ferreira sold 4,161 shares of Afya stock in a transaction dated Monday, October 5th. The stock was sold at an average price of $13.30, for a total transaction of $55,341.30. Following the completion of the transaction, the insider owned 35,000 shares in the company, valued at approximately $465,500. The trade was a 10.63% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website.
Institutional Trading of Afya
Several hedge funds have recently made changes to their positions in AFYA. Public Employees Retirement System of Ohio purchased a new position in shares of Afya during the 2nd quarter valued at $67,000. R Squared Ltd raised its position in shares of Afya by 37.0% in the third quarter. R Squared Ltd now owns 60,114 shares of the company's stock worth $724,000 after buying an additional 16,250 shares in the last quarter. Entropy Technologies LP purchased a new stake in shares of Afya in the third quarter worth $246,000. Engineers Gate Manager LP purchased a new stake in shares of Afya in the second quarter worth $325,000. Finally, Marshall Wace LLP bought a new stake in Afya during the third quarter valued at $399,000. 88.02% of the stock is currently owned by institutional investors.
About Afya
(
Get Free Report)
Afya Limited is a Brazilian medical education and digital health company. Its education business offers undergraduate medical degree programs, medical residency preparation, postgraduate courses and continuing education for health professionals. The company also provides digital tools and services for medical students and practicing physicians, including clinical reference, practice-management and learning resources. These offerings support professionals at different stages of their medical careers.
See Also

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Afya, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Afya wasn't on the list.
While Afya currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
A strong long-term portfolio starts with companies that can survive recessions, inflation, changing consumer habits, and shifting market leadership.
This report names seven blue-chip stocks across technology, retail, consumer staples, healthcare, networking, sporting goods, and utilities that offer investors a mix of stability, income, growth, and staying power.
Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.
Link copied to clipboard.